Researchers from the Clínic-IDIBAPS, along with researchers from the Dana Farber Cancer Institute (DFCI) in Boston, have published a review on dual H1
The DEFINITIVE project, led by IDIBAPS, will be conducted across 44 hospitals in a total of 7 European and associated countries to demonstrate that u1
The spin-off helmed by Aleix Prat received the award in the category of Collaborative Research in Transfer for Development for its HER2DX breast canc1
HER2DX® was highlighted in Times 'Medical Care' category, which publicizes inventions that are successfully implemented in medical practice.
The new test, called HER2DX, analyzes RNA on 27 genes to predict survival outcomes and the likelihood that patients will respond to treatment.
Reveal Genomics’ first goal will be to develop diagnostic tools based on complex genomic data for patients with advanced breast cancer.
